Key Takeaways
- Domestic strength, U.S. drag: India business grew 13% YoY, outperforming the IPM by 500 bps, while U.S. revenue declined 0.9% YoY in rupee terms due to severe price erosion.
- Margin guidance cut: Management flagged that the FY23 EBITDA margin guidance of 16-16.5% is challenging and could see a downside of ~100 bps due to U.S. price erosion and elevated costs.
- Cost savings identified: A concrete plan targeting Rs. 200-250 crore in cost savings over the next 12 months is underway, with announcements on plant restructuring and network optimization expected in 2-3 months.
- U.S. business at a trough: Management believes the U.S. business has "hit rock bottom" and profitability should improve from here, though they acknowledge they don't know if it could get worse.
- What to watch next quarter: The pace of U.S. price erosion, the rollout of cost-saving initiatives, and whether the second-half margin recovery materializes as guided.
India Business: The Growth Engine
- Broad-based outperformance: The 13% YoY growth was driven by market share gains across all acute therapies and 4x market growth in the Antidiabetic segment, fueled by new launches including strong execution on Sitagliptin.
- Chronic portfolio momentum: Barring Cardiology, all chronic divisions (diabetology, dermatology, CNS, uro) delivered healthy double-digit growth in both Q1 and Q2, driving overall Chronic growth of around 19-20%.
- Acute divisions mixed: Divisions dependent on anti-infectives, pain, and multivitamins saw muted growth due to a high base from last year's COVID/Omicron/dengue-driven sales, while acute divisions based on orthopedics or gastrointestinal delivered healthy double-digit growth.
- Price increase flowing through: The NRV component contributed 5.3% of the total 10% growth in Q2, indicating that the impact of price increases is now materializing in revenue.
- Field force expansion: The company added around 1,000 medical representatives in the last 12 months, with productivity growth expected to track the 10-12% growth guidance over the next 3 years.
Sandeep Singh: "We have identified around Rs. 200 crore to Rs. 250 crore of cost savings, which are doable in the next 12 months."
U.S. Business: Price Erosion and a Trough Call
- Price erosion was severe: Q2 FY23 price erosion was between 10% to 15% and probably more than 15%, because the prior-year quarter had a couple of first-to-market exclusive launches that have since gone through rapid price erosion.
- Base business headwinds: The base business had significant contribution from ibuprofen and famotidine in the prior year, making YoY comparisons difficult; sequentially, the U.S. business showed growth.
- Gross margin hit: The 4.7% decline in gross margin was almost entirely due to U.S. price erosion (impact of 4.8%), as higher material costs were well compensated by a favorable mix.
- Calibrating investment: Management is controlling capital allocation to the U.S. and holding back R&D investment, acknowledging this will have some impact on growth; the task is to invest smarter while still expecting revenue and margin growth.
- Limited near-term catalysts: A shared exclusivity launch this quarter was not significant for revenue or margin, and the generic Dabigatran launch was limited to single-digit market share due to raw material supply chain constraints.
Sandeep Singh: "It would sound funny in hindsight, but we do think we have hit rock bottom. I hope I'm correct, so it will certainly improve from now, but could it get worse, we don't know."
Margin Walk and Cost Structure
- Gross margin pressure: Fell 4.7% in the quarter, entirely from U.S. price erosion; domestic margins saw no overall pressure as a 1.7-1.8% higher material cost impact was compensated by a better product mix.
- Other expenses elevated: Rose to 24.3% of revenue from 22.3% YoY because marketing expenses were higher and traveling expenses normalized from 80-85% levels during COVID to full activity; management stated the normal range is 23.5% to 24% and expects to maintain 23% to 24% going forward.
- Material costs sticky: Anti-infective prices remain elevated and have not returned to pre-COVID levels; materials procured at high prices in November, December and January were consumed in sales during the quarter, though the 2% impact on gross margin from material costs is expected to come down going forward.
- Second-half margin recovery expected: Drivers include the complete impact of price increases seen in Q3, some betterment in material costs, lower sales incentives versus the first half, and an accounting cutoff benefit that gives additional EBITDA margin in Q3 and Q4.
Rajesh Dubey: "Our guidance of 16% to 16.5%, we feel if this situation is going to continue, then it will be difficult for us to be there and there could be minus side to extent of 100 basis points or something like that."
Cardiology: A Division in Transition
- Performance slipped: Cardiology lost one rank on a half-year basis, with the major challenge coming through anticoagulants where Dabigatran sold very well during COVID but new anticoagulants are now entering and impacting the business.
- Strategic pivot underway: The company is changing its approach to focus on anti-hypertensives (Olmisartan, Telmisartan) and lipid management (Rosuvastatin) as core growth drivers.
- New launches to provide cover: Apixaban has been launched and in the first IQVIA data, Alkem is unit #1; Sacubitril/Valsartan for heart failure is an upcoming launch that management believes can be another blockbuster.
Strategic Initiatives and Pipeline
- Cost savings program: Concrete steps include networking optimization and plant restructuring, with announcements expected in the next 2-3 months; management stated there will be no significant impact on the existing revenue base from these initiatives.
- Diabetes growth plan: Linked to the expiry of innovative brands, with one big cardiovascular drug going off-patent in Jan-Feb.
- Biosimilar denosumab: Phase I and Phase III trials are running in parallel; management believes field force requirements will go off by 2026 and is not looking for a partner right now.
- China dependency: Management acknowledged that things will improve but won't change materially in the next 2 years, stating there will always be Chinese dependency and the company will never be fully out of it.
- M&A stance: Not much activity expected; the company will do things organically, and any acquisition will be very small compared to peers for the foreseeable future.
Sandeep Singh: "Honestly, next 6 to 12 months, we don't see anything dramatically changing that something can kind of turn the tables."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 EBITDA margin | 15-15.5% on a full-year basis, with second-half margins much higher than the first half | FY23 |
| FY24 EBITDA margin | Get back to 18% or 18% plus | FY24 onwards |
| Cost savings realization | Rs. 200-250 crore identified, doable; concrete steps to be announced | Next 12 months; announcements in 2-3 months |
| Other expenses range | Maintained in the 23% to 24% range | Going forward |
| India business outperformance | Carry forward the outperformance of the domestic franchise | Second half of FY23 |
| U.S. business trajectory | No dramatic change expected that can turn the tables; depends on market conditions and approvals | Next 6-12 months |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| India business revenue growth | 13% YoY |
| US business revenue growth | -0.9% YoY in rupee terms |
| Domestic franchise outperformance vs IPM | 500 bps |
| Antidiabetic segment growth vs market | 4x the market growth rate |
| Gross margin decline | 4.7% YoY |
| Price erosion impact on gross margin | 4.8% |
| Higher material cost impact on domestic margin | 1.7% to 1.8% |
| EBITDA margin, H1 FY23 | 11.6% |
| EBITDA margin guidance, FY23 | ~15% to 15.5%, revised down from ~16% to 16.5% |
| EBITDA margin guidance, FY24 | 18% plus, held |
| Cash generated in the quarter | ₹400 cr |
| Cash position, end of September 2022 | ~₹1,350 cr |
| Identified cost savings target | ₹200 cr to ₹250 cr, doable in next 12 months |
| US business share of total revenue | 25% |
| US price erosion | 10% to 15% and probably more than 15% |
| Chronic division growth | ~19% to 20% |
| NRV component of domestic growth | 5.3% out of total 10% growth |
| Other expenses as a percentage of revenue | 24.3%, vs 22.3% in Q2 last year |
| Acute share of domestic business | 84% |
| Chronic share of domestic business | 16% |
| Direct import from China | 10% to 12% of raw material procurement |
| Indirect China influence on API | 65% to 70% |
| Total MR strength | ~11,000 |
| MRs added, last 12 months | ~1,000 |
| Fully loaded cost per medical rep | ₹6.5 lakh to ₹7 lakh (CTC plus operational cost) |
| MR breakeven time | 2.5 to 3 years |
| R&D spend guidance | 5% to 6% of revenue |
| Acute MR productivity | ~₹6.5 lakh |
| Chronic MR productivity | ~₹3.8 lakh to ₹3.9 lakh |
| Domestic growth guidance, next 3 years | 10% to 12% |